YAP and its downstream target AXL play an important role in the development of resistance to EGFR TKIs, suggesting that a combined inhibition of EGFR and the YAP/AXL axis could be a therapeutic strategy for selected NSCLC patients [62]. This evidence concerns the gene EGFR and non-small cell lung carcinoma.